中国肺癌杂志2023年3月第26卷第3期Chin】Lung Cancer,March2023,Vol.26,Na.3·165-D01:103779/1issn1009-3419.2023.102.12·Expert Consensus·Expert Consensus on Prevention and Treatment ofCOVID-19 Infection in Patients with Lung CancerNon-small Cell Lung Cancer Expert Committee of Chinese Society of Clinical OncologyChina Medical Education AssociationAbstractCorona virus disease 2019 (COVID-19)infection has become a major public health issue affecting human health.The main goalof epidemic prevention and control at the current stage in China is toprotect people's health and prevent severe casesPatientswith lung cancer who receive antitumor therapy have low immunity,and the risk of severe illness and death once infected ismuch higher than healthy people,so they are vulnerable to COVID-19 infection.At present,less attention has been paid to theprevention and treatment of COVID-19 infection in patients with lung cancer in domestic guidelines and consensus.Based onthe published data in China and abroad,we proposed recommendations and formed expert consensus on the vaccination ofCOVID-19,the use of neutralizing antibodies and small molecule antiviral drugs for patients with lung cancer,for physician'sreference.Key words Corona virus disease 2019;Lung neoplasms;Prevention;Treatment;Expert consensusI Introductionwith lung cancer,considering the relevant data in Chinaand abroad and China's epidemic prevention and controlLung cancer is a malignant tumor with high morbidity andpolicies,the Non-small Cell Lung Cancer (NSCLC)Expertmortalityin China and other countries around the world.TheCommittee of Chinese Society of Clinical Oncology(CSCO)5-year survival rate is only 19%.Since the rapid spread ofand China Medical Education Association have formedCorona virus disease 2019(COVID-19)infection worldwide,the first expert consensus on prevention and treatmentit has become the third cause of death in the United States inof COVID-19 infection in patients with lung cancer after202112.Due to the old age ofmost patients with lung cancer,extensive consultation.multiple underlying diseases,immunosuppression caused byThe principles of expert recommendation and evidencethe antitumor therapy,repeated visits to hospitals,and otherrating in this consensus are as follows:factors,the risk of COVID-19 infection,severe illness,andRecommendation level:A=strong;B=moderate;death ofpatients with lung cancer is much higher than that ofC=optional.Evidence level:I=1 or more randomizedhealthy peopletrials without significant limitations;Ila=otherVaccination is still the main effective way to preventrandomized trials or subgroup analyses of randomizedCOVID-19 infection and severe illness in patients with lungtrials;IIb=non-randomized trials or observationalcancer.However,patients with cancer are often excludedcohort studies;III=expert opinion.from the clinical trials of vaccine development.The efficacyand safety of vaccination in patients with cancer remain to2 Epidemiology oflung cancer during COVID-19be stu
